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Purpose: To investigate drug use, prescribing patterns, and comorbidities among patients with 
migraine in a large pharmacy claims database.
Methods: 104,625 migraine subjects (identified according to the criteria in the International 
Classification of Diseases, Ninth Revision [ICD-9] for migraine or migraine-specific acute 
medication use) and an equal number of control patients were selected from a de-identified 
claims database; the prevalence of patients with migraine-specific claims was determined. 
Patient demographics, migraine-related medication use, other psychotropic medication use, and 
comorbidities over a 12-month period were compared between the migraine population and the 
control group and between migraine subgroups.
Results: Of the study population, 3.5% had a migraine diagnosis according to the ICD-9 or 
received a migraine-specific acute medication. Compared with controls, migraine patients 
had significantly greater disease comorbidity and higher use of prescription nonsteroidal anti-
inflammatory drugs and controlled painkillers; they were also more likely to receive medications 
used to prevent migraines and other nonmigraine psychotropic medications, such as anxiolytics 
and hypnotics. Among migraine patients, 66% received acute migraine-specific medication while 
only 20% received US Food and Drug Administration–approved migraine preventive therapy. 
Notably, one-third of high triptan users did not receive any kind of preventive medication. 
Multiple medical and psychiatric comorbidities were observed at higher rates among migraine 
sufferers. In addition to significantly higher utilization of antidepressants compared with controls, 
migraine patients also received significantly more other psychotropic drugs by a factor of 2:1.
Conclusion: Acute migraine medications are commonly used and frequently dispensed at 
rates that raise concern of overuse; high use is often seen without any preventive medications. 
Furthermore, use of US Food and Drug Administration–approved preventive medications is 
low. Finally, patients with migraine are significantly more likely to receive other psychotropic 
medications. These findings suggest efforts to optimize the management of migraines could 
address appropriate use of triptans, increased and more effective use of migraine preventive 
medications, and better understanding of the use of other psychotropics.
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Introduction
Migraine is a common and frequently chronic neurovascular condition with episodic 
exacerbations of varying intensity and frequency. In the USA, one in every four 
households includes a family member who suffers from migraine.1 The World Health 
Organization estimates that 324 million people have migraine, with prevalence rates 
among women two to three times greater than among men.2 Migraine is a major 
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source of disability and lost working days for women aged 
15–44 years in high-income countries, second only to unipo-
lar depressive disorders.2 The frequency of migraine episodes 
ranges from daily headaches to less than a single migraine 
per month. Migraine management represents an important 
public health priority: in the insured US population alone, 
migraine-associated health care expenses amount to an esti-
mated US$11 billion in direct costs and almost US$12 billion 
in indirect costs.3,4
Medication management of migraine may be classified 
into treatment of the acute headache phase and long-term 
migraine prevention. The introduction of the highly effective 
triptan class of medications for treatment of acute migraine 
has been followed by attempts in clinical practice to balance 
their efficacy with their unfavorable features: higher drug 
costs, potential drug interactions and adverse events, and 
symptomatic medication overuse with subsequent risk of 
clinical progression of the migraine condition from episodic 
to a chronic daily headache (CDH).
Only four medications (divalproex sodium,   propanolol, 
timolol, and topiramate) carry US Food and Drug 
Administration (FDA) indications as migraine preventive 
therapies. In addition to these approved preventive therapies, 
medications from several classes of drugs (including 
anticonvulsants, antidepressants, beta-blockers, and other 
antihypertensives) are frequently prescribed for migraine 
prophylaxis. Evidence-based approaches, such as the US 
Headache Consortium Guidelines, have been developed 
to describe circumstances warranting migraine preven-
tive therapy.5 However, results of the American Migraine 
Prevalence and Prevention study suggest that, although 40% 
of migraine sufferers are eligible for migraine preventive 
therapies, only 13% receive such therapies.6
The present study investigates pharmacologic treatment 
patterns from 2008 to 2009 in insured patients with migraine 
using a large pharmacy and medical claims database. The 
aim was to study patients who received medical care for their 
migraines as evidenced by a medical diagnosis of migraine 
or use of migraine-specific acute medications (MSAMs). 
Prior research suggests that this subset of migraine patients 
has higher medical care utilization and costs than patients 
without claims evidence of migraine-related medical care.7 
The primary objectives were to evaluate drug use patterns 
among migraine and control populations, focusing on triptans 
and other acute migraine medications, FDA-approved 
  preventive therapies, commonly used “off-label” preventive 
medications, preventive medication use among high triptan 
users, and other psychotropic medications.
Methods
This study used a large de-identified medical and pharmacy 
claims database maintained by Medco Health Solutions Inc, 
Franklin Lakes, NJ, which contains more than 36 months 
of pharmacy and medical claims for over 13 million lives 
covered by more than 450 health plans. Pharmacy data were 
obtained for all medication claims filed with patient health 
plans receiving services from Medco Health Solutions Inc 
through both retail and mail channels. Medical claims for 
inpatient, outpatient, emergency department and nursing 
home visits, as well as the occurrence of laboratory and 
diagnostic testing were also available from health plans. 
Information arising from health care paid for through 
Medicare or entirely out of pocket without filing a claim 
through the health plan was not included in this database.
Claims from 2008 to 2009 were analyzed for patients 
aged between 18 and 62 years as of January 1, 2008 to 
avoid incomplete medical claims due to dual coverage by 
Medicare. Patients were required to have made at least one 
medical and one pharmacy claim during 2008. Patients 
with a medical claim for migraine and/or pharmacy claim 
codes for MSAMs filed between January 1, 2008 and 
December 31, 2008 were included in the migraine study 
cohort (Appendix 1). The control population was randomly 
selected from those patients aged 18–62 years without any 
migraine-specific claims   during 2008–2009 in a 1:1 ratio 
to the migraine cohort. Control subjects were not matched 
to migraine patients for gender, age, or other variables. All 
subjects were followed and their prescription patterns and 
medical use tracked during a 12-month follow-up period that 
started as of the date of their first migraine-specific claim in 
2008 (for the migraine cohort) or a randomly generated date 
in 2008 (for the control group). Patients not continuously 
eligible for payor-funded health care during the 12-month 
follow-up period were excluded from the migraine cohort 
and the control group.
To describe prescription patterns during the follow-up 
period,  use  of  preventive  medications  (including 
FDA-approved and nonapproved classes), acute medications 
(including triptans and ergots), any migraine medications 
(acute or preventive), nonsteroidal anti-inflammatory 
drugs (NSAIDs), controlled painkillers (oral forms), and 
major classes of psychotropic medications not routinely 
used for migraine treatment (Appendix 2) were identified. 
Use of these medications was defined as the presence of 
one or more claims for the medication during the 12-month 
follow-up period. The total days of supply patients received 
for triptans, all acute medications, NSAIDs, and controlled 
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painkillers was calculated. High triptan use was defined a 
priori as   dispensing of triptan pills, sprays, or injections at 
a level that suggested the patient was treating more than 
24 headaches during any 90-day rolling period. For this 
calculation, it was assumed that a quantity of two pills or 
injections (regardless of strength or specific triptan), two 
sprays of nasal sumatriptan, one subcutaneous injection of 
zolmitriptan, or one spray of nasal zolmitriptan was used 
for each headache. For each patient, the specialty of the 
prescriber of the first claim for psychotropic medications 
and MSAMs was identified.
International Classification of Diseases, Ninth Revision 
(ICD-9) codes associated with all medical claims for each 
patient during the follow-up period were evaluated to 
identify key comorbid conditions, defined a priori based 
on potential comorbidities of interest and reports in the 
literature (Appendix 3).8 Chronic disease score (CDS) 
was calculated from pharmacy claims data by methods 
similar to the original CDS developed by Von Korff and 
colleagues.9
Patient demographics, medication use, prescriber 
specialty, and comorbidities were compared between the 
migraine and the control groups. Migraine patients were 
stratified based on the types of migraine medications they 
received during the follow-up period (acute medications only, 
acute and preventive medications, preventive medications 
only, no migraine medications) and the characteristics of 
those who did not receive any migraine medications were 
compared with the three other medication treatment groups. 
Continuous variables were compared using the unpaired 
t-test. Categorical variables were compared using the chi-
square test. All analyses were performed with SAS (v 9.1; 
SAS Institute Inc, Cary, NC) software.
Results
Migraine patients compared with controls
The authors identified 158,426 patients in the database 
with a migraine ICD-9 diagnosis and/or MSAM claim, 
which   represented a 3.5% migraine prevalence rate among 
all patients with at least one medical and one medication 
claim during 2008 (Table 1). Of these patients, 104,625 met 
study criteria as migraine subjects after filters were applied 
for continuous eligibility during the follow-up period, age 
range restrictions, and presence of recorded gender. The 
control group consisted of 104,625 randomly selected 
patients without migraine. These groups, along with the four 
  subgroups of migraine patients based on migraine treatment, 
are shown in Table 2.
The mean age of migraine subjects was 44 years and 
83% were women. Compared with the control population, 
the migraine group had higher mean CDS, a higher per-
centage of patients with NSAID and controlled analgesic 
medication use, and received a significantly greater days’ 
supply of these pain medications. Migraine sufferers were 
significantly more likely to have ICD-9 diagnoses for eight 
of the ten comorbid conditions studied than the control 
population – only diabetes and hypertension were observed 
at higher rates in the control population.
More than half (58%) of the migraine group received 
pharmacotherapy that could be used for migraine prevention, 
though only one in five received medication approved by 
the FDA for migraine prophylaxis: 15% received an FDA-
approved preventive anticonvulsant and 5% received an FDA-
approved preventive beta-blocker antihypertensive (Table 3). 
Half of the migraine group received pharmacotherapy 
that could be considered an off-label migraine preventive: 
39%, 15%, 11%, and 1% of all migraine subjects received 
antidepressants, other antihypertensives, other anticonvulsants, 
and/or other agents, respectively. In the control population, 
the use of any migraine preventive medication for any reason 
was significantly lower (33%, rounded), with only about 1% 
(rounded) receiving an FDA-approved migraine preventive 
medication and 33% (rounded) receiving drugs that are 
potential migraine preventive medications. Antidepressants 
were used less frequently in control compared with migraine 
patients (18% versus 39%, respectively).
Compared with the controls, the migraine group had 
significantly higher rates of use for other psychotropic drugs 
(excluding antidepressants, topiramate, and divalproex), with 
30% receiving an anxiolytic, a new generation hypnotic, 
Table  1  Migraine  population  from  a  national  pharmacy  and 
medical claims database with migraine prevalence calculation
Applied criteria Number of patients
At least one medical and one medication  
claim during 2008
4,542,788
Presence of acute migraine medication  
claim and/or migraine ICD-9 diagnosis
158,426
Continuously eligible during follow-up period* 124,339
gender not missing and age = 18–62 years as  
of January 1, 2008: migraine study cohort
104,625
Calculated prevalence of migraine patients  
(n = 158,426)*
3.5%
Note: *Follow-up period for the study was defined by the 12 months immediately 
following the start date of first migraine-specific claim in 2008 (migraine cohort) or a 
randomly generated date in 2008 (control group); this insured that all study subjects 
had a minimum of 12-months’ continuous data available for analysis.
Abbreviation: ICD-9, International Classification of Diseases, Ninth Revision.8
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
665
Patients with migraine and pharmacologic treatment patternsNeuropsychiatric Disease and Treatment 2011:7
an antipsychotic, a mood stabilizer and/or a stimulant 
drug (Table 2). Among patients receiving psychotropic 
medications, migraine patients were more likely than controls 
to have their psychotropic medication prescribed by a 
neurologist (7% versus 2%, respectively; data not shown).
Comparison of migraine treatment 
groups
Fifteen percent of migraine patients did not receive any 
MSAM or preventive medication therapy, 18% received 
only migraine preventive therapy (either FDA-approved or 
other potential preventive medication), 27% received only 
acute migraine medications, and 39% received acute and 
preventive medications (Table 2). The nontreated group was 
younger and had a lower percentage of women compared 
with the other three groups.
Prescribing of NSAIDs and controlled painkillers was 
similar in the untreated group and the group dispensed 
acute migraine medications only; both groups received less 
of these medications than those in the acute and preventive 
or preventive medications-only groups. The prevalence of 
controlled painkiller use among the migraine patients who 
received preventive medications was above 50%.
Compared with patients receiving acute medication only, 
a greater percentage of the untreated migraine sample had 
comorbidities (Table 2); compared with patients receiving 
acute and preventive medications and preventive medications 
only, the untreated group had lower proportions with 
comorbidities. A lower percentage of migraine patients in the 
untreated and acute medication groups used psychotropics 
(excluding antidepressants) than in the two groups that 
received preventive medication. Across all four groups, more 
Table 2 Study characteristics of migraine and control subjects
Control group  
(no migraine)
Migraine patients
All migraine Migraine treatment status
None Acute only Acute and  
preventive
Preventive 
only
N (%) 104,625 104,625 15,847 (15%) 28,626 (27%) 40,855 (39%) 19,297 (18%)
Female 57% 83%† 77% 82%* 87%* 81%*
Age (years) 44.5 (12) 43.8 (11)† 40.6 (12) 43.1 (11)* 45.4 (11)* 44.5 (11)*
CDS 11 (16) 23 (21)† 7 (13) 17 (14)* 33 (23)* 22 (22)*
NSAID use 15% 24%† 20% 19%€ 28%* 27%*
  Days 7 (31) 13 (41)† 7 (26) 8 (30)* 17 (50)* 14 (42)*
Controlled pain med use 25% 47%† 36% 38%¥ 56%* 53%*
  Days 8 (38) 27 (70)† 12 (47) 11 (41)€ 37 (80)* 41 (87)*
Any psychotropic 14% 30%† 15% 17%* 40%* 39%*
  New gen hypnotics 6% 13%† 5% 8%* 19%* 16%*
  Anxiolytics 9% 20%† 10% 10% 27%* 28%*
  Antipsychotics 0.9% 3%† 0.4% 0.3% 4%* 4%*
  Mood stabilizer 0.2% 0.5%† 0.1% 0.1% 0.9%* 0.9%*
  Stimulants 0.8% 1.4%† 0.7% 0.6% 2%* 2%*
Comorbidities
  Depression 7% 16%† 4% 3%* 24%* 26%*
  Bipolar 1% 2%† 0.5% 0.3%* 3%* 4%*
  Anxiety 6% 12%† 6% 4%* 16%* 19%*
  Chronic pain 0.6% 2%† 1%  0.5%* 3%* 4%*
  Arthritis 10% 14%† 11% 9%* 18%* 20%*
  Fibromyalgia 4% 10%† 7% 5%* 12%* 13%*
  Sinusitis 14% 24%† 22% 20%¥ 26%* 26%*
  Hypertension 24% 21%† 13% 9%* 26%* 36%*
  Diabetes 9% 5%† 4% 2%* 6%* 10%*
  Epilepsy 0.8% 2%† 1% 0.5%* 3%* 5%*
Notes: All values for age, CDS, days of NSAID and days of pain medication are reported as mean and standard deviation (SD). Days refer to the total days supplied 
of each type of medication over the 12-month observation period. Pain medications include oral Drug Enforcement Administration (DEA)-controlled painkillers; any 
psychotropics are based on .1 claim for any psychotropic medication in each class during the 12-month observation period (see Appendix 2 for listing of study drugs). 
Comorbidities were determined by presence of ICD-9 codes during the 12-month observation period (see Appendix 3). Comparisons were made between (1) all migraine 
group and control group, and (2) each migraine treatment group and no migraine treatment group. †P value , 0.0001 compared with control group; *P value , 0.0001 
compared with no migraine treatment group; ‡P value , 0.001 compared with no migraine treatment group; ¥P value , 0.01 compared with no migraine treatment group;   
€P value , 0.05 compared with no migraine treatment group.
Abbreviations: CDS, chronic disease score; NSAID, non-steroidal anti-inflammatory drugs; ICD-9, International Classification of Diseases, Ninth Revision.8 
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than half of the patients who received a psychotropic drug 
were initially prescribed the drug by a primary care provider 
(data not shown).
Among migraine subjects, two-thirds received acute 
treatment at some point during the study period and 60% 
received triptans (Table 4). Sixteen percent (rounded) of 
all migraine patients and 26% of triptan users (16,526 and 
62,639 patients, respectively) received triptans in amounts 
suggesting the acute treatment of more than 24 headaches in 
a 90 day period (defined as high triptan users). Among the 
16,526 migraine patients identified as high triptan users, 33% 
(5,415/16,526) did not receive any migraine preventive drug 
during the study period.
Discussion
Prevalence, characteristics, and 
comorbidity
The 3.5%, 1-year period prevalence of migraine in this large 
US pharmacy claims database is, as expected, lower than 
the ∼13% prevalence reported from recent US cross-sectional 
Table 3 Preventive medication (med) use in migraine and control patients
Control patients,  
n = 104,625
All migraine patients,  
n = 104,625
Acute and preventive,  
n = 40,855 (68%)
Preventive only, 
19,297 (32%)
Any preventive med, n % 34,968 (33%) 60,152 (58%)* – –
FDA-approved preventive 1% 20%* 36% 31%
  Anticonvulsant 0.7% 15%* 28% 24%
    Topiramate 0.4% 14%* 25% 21%
    Semisodium valproate 0.4% 2%* 4% 4%
  B-blocker 0.6% 5%* 10% 8%
    Propanolol 0.6% 5%* 10% 8%
    Timolol 0% 0.07%* 0.1% 0.1%
Off-label preventive 33% 50%* 87% 88%
Antidepressants 18% 39%* 70% 64%
  SSRI 12% 23%* 40% 37%
  SNRI 3% 10%* 18% 16%
  TCA 1% 8%* 14% 12%
  MAOI 0.02% 0.05%* 0.1% 0.1%
  Others 5% 11%* 20% 18%
Antihypertensives 17% 15%* 23% 30%
  Alpha 2 agonists 0.1% 0.2%* 0.3% 0.5%
  ACEI 12% 8%* 12% 17%
  Beta-blockers (non-FDA) 5% 6%* 9% 12%
  Calcium channel blockers 4% 3%* 4% 7%
  Combinations without diuretic 0.4% 0.3%* 0.3% 0.7%
Other Anticonvulsants 4% 11%* 18% 20%
Others 0.4% 1%* 2% 3%
Note: *P value , 0.0001 comparing values for all migraine patients with control patients.
Abbreviations: SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant; MAOI, monoamine oxidase 
inhibitor; ACEI, angiotensin-converting enzyme inhibitors. 
Table 4 Acute migraine-specific medication use
All migraine patients, 
n = 104,625
Acute medication only,  
n = 28,626
Acute and preventive medication, 
n = 40,855
Any acute medication 69,481 (66%)† 28,626 (27%¥)* 40,855 (39%¥)
  Days of supply, mean (SD) 59 (84) 76 (82)* 98 (94)
Any triptan use 62,639 (60%€) 25,795 (90%€) 36,844 (90%€)
  Days of supply, mean (SD) 57 (84) 74 (83)* 94 (95)
High triptan use‡ 16,526 (16%€) 5,415 (19%€)* 11,111 (27%€)
Notes: †Values are n (%) unless otherwise specified; ‡high triptan use was defined as the dispensing of triptans that treated more than 24 headaches during any 90-day 
rolling period. Two pills or injections (regardless of strength or specific triptan), 2 sprays of nasal sumatriptan, 1 subcutaneous injection of zolmitriptan, or 1 spray of nasal 
zolmitriptan was defined as the amount of drug used for one headache; ¥proportion of all migraine patients; €proportion of column total; *P value , 0.0001 comparing values 
for acute medication only versus acute and preventive medication groups.
Abbreviation: SD, standard deviation. 
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survey studies.10 This lower prevalence is partly because only 
half of migraine sufferers receive care from a physician and 
less than half use prescription medications.10 Others have 
shown that migraine patients who have an ICD-9 diagnosis 
or receive MSAMs use more health care resources and 
probably have more severe disease than those identified by 
interview criteria alone.8,11,12 The migraine patients identified 
in this study were most likely to be those with the greatest 
migraine-related morbidity.
Consistent with other studies, the present analysis 
found a striking female preponderance among migraine 
sufferers, with a female to male ratio of 4.9:1.8,11 
Migraine patients had significantly higher CDS scores 
than the control   population, indicating greater aggregate 
comorbidity. Originally validated for use as a predictor 
of physician-rated disease status, self-rated health status, 
hospitalization, and mortality,9 the observed difference 
in CDS scores confirms previous observations of greater 
clinical complexity and overall poorer health status among 
migraine sufferers. Migraine patients had significantly 
higher rates of epilepsy, psychiatric disorders (such as 
anxiety, bipolar spectrum disorder, and depression) and 
painful conditions (such as chronic pain, fibromyalgia, 
arthritis and sinusitis). In addition, compared with the 
control group, migraine patients had significantly higher use 
of other analgesics – NSAIDs and US Drug Enforcement 
Administration-controlled painkillers. The use of opioids 
in patients with migraine is of particular concern due to 
the potential for development of tolerance, addiction, and 
dependence, as well as worsening of the primary headache 
disorder.12,13 There is also mounting evidence that opioid 
use in migraine may lead to medication-overuse headache, 
decreased responsiveness to other migraine medications, 
and poorer long-term outcomes.15–19
The finding in this study of increased prevalence of 
epilepsy among migraine patients compared with the control 
group (2% versus 0.8%, respectively) is consistent with a 
prior study (5.9% versus 0.5%, respectively),20 although the 
magnitude of difference was much lower in the present study. 
This is an important medical comorbidity to recognize among 
migraine sufferers since many of the psychotropic drugs (such 
as antidepressants and antipsychotics) used either as off-
label for migraine preventive therapy or to treat psychiatric 
comorbidity have the potential to lower seizure threshold.21 
Some caution must be used, however, when interpreting 
comorbidity data from individuals seeking medical treatment 
for two separate conditions due to a potential Berkson’s 
selection bias – such patients often demonstrate a high rate 
of association between two medical conditions that may be 
independent in the general population.22
This study found a lower prevalence of hypertension 
among migraine sufferers compared with the control group. 
Prior studies have demonstrated inconsistent associations 
between hypertension and migraine, although more recent 
studies suggest hypertension may be associated with 
chronic daily headache (CDH) and a potential risk factor for 
chronification of migraine.23,24
The potential association between migraine and diabetes 
has been poorly studied. Historically, authors of clinical 
observations and small studies have commented on the rarity 
of migraine among patients with diabetes mellitus, suggest-
ing diabetes may offer some protection against migraine.25,26 
The present study found that patients with migraine in the 
Medco database were almost two times less likely to have 
diabetes than those in the control group. Whether glucose 
homeostasis plays a contributing role in the pathophysiol-
ogy of migraine remains unknown and warrants further 
exploration.
The use of migraine acute and preventive 
medications
Only 20% of patients with migraine received an FDA-
approved drug for migraine prevention. To the authors’ 
knowledge, this is the first claims-based study to report on 
the prevalent use of FDA-approved migraine   preventive 
therapies in a population of diagnosed and/or treated 
migraine patients. This finding supports earlier reports, such 
as the American Migraine Prevalence and Prevention study, 
which state that a minority of migraine patients receive 
FDA-approved preventive therapy.7,27 When broadening the 
definition of preventive medications to include any medi-
cation potentially used for migraine prevention, more than 
half of migraine patients received these medications. Most 
of the “off-label” migraine preventive drugs used in the 
present study were antidepressants and it was unable to be 
determined if their use was for migraine or for a psychiatric 
condition.
Lafata and colleagues also evaluated preventive 
medication use among patients with migraine and reported 
that only 13.4% of all migraine cases and 12.4% of control 
patients were users of migraine preventive medications.7 They 
studied patients from a single nonprofit health plan serving 
residents of southeast Michigan, used structured telephone 
interviews to characterize patients as migraine or control, and 
evaluated use of preventive medications using linked health 
insurer claims data. The higher prevalence of any preventive 
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medication use among migraine and control patients in the 
present study may be explained by several factors:
•	 The current study focused on migraine patients who 
had received either a diagnosis of migraine and/or 
used MSAMs, rather than patients identified by phone 
interview, and were therefore more likely to receive 
preventive medication.
•	 Lafata et al required two claims for the same medication 
class to count as preventive medication use, while this 
study required only one.
•	 Control patients in the present study were required to 
have at least one prescription claim and therefore were 
more likely to receive commonly prescribed medications, 
such as antidepressants.
A significant proportion of migraine patients in the pres-
ent study received treatment with either FDA-approved and/
or other potential migraine preventive drug(s), however, the 
authors’ findings show that preventive medications are still 
underused in a sizable portion of patients with migraine.
Most concerning is the lack of preventive medication 
use in one of every three patients who received amounts of 
triptans suggesting a headache frequency of greater than 
24 in a 90-day period. Patients who have more than two 
acute migraine attacks per month and/or whose daily activity 
is compromised by headaches are universally considered 
candidates for preventive medication.6,7 Therefore, a 
significant number of patients eligible for preventive therapy 
were either not prescribed or did not fill prescriptions for 
preventive medication during the study period. Further, in 
the migraine population in this study receiving only acute 
migraine medication, 19% were high triptan users. This is 
of concern given the potential risk for medication-overuse 
headache or CDH. Population studies show that about 3% 
of patients with episodic migraine develop CDH over 1 year 
of follow-up.28 CDH is linked to excessive acute migraine 
medication use, greater disability, and higher rates of medical 
comorbidity (including depression, anxiety, and fibromyal-
gia), as well as elevated suicide risk.19,29–33
Interestingly, migraine patients receiving preventive drugs 
used significantly greater amounts of NSAIDs and controlled 
painkillers compared with those not obtaining preventive 
medications. Prior studies have demonstrated reduction 
in triptan use in patients who start migraine preventive 
medications.34–37 This study found that migraine patients 
using both preventive and acute medications received more 
triptans and had a greater percentage of high triptan users 
than patients receiving acute medications alone. There are 
several possible explanations for these findings:
•	 channeling bias, where those who have worse migraine 
symptoms are also more likely to receive preventive 
medications
•	 the possibility that the preventive medications were 
started later in the follow-up year, after the high acute 
medication use
•	 the potential for residual migraine symptoms even with 
preventive medication use.
Nonadherence with preventive medications could also 
contribute to greater utilization of acute analgesic medica-
tions, including triptans.
The “untreated” but diagnosed  
migraine population
In this study, about one in six migraine patients did not receive 
any migraine-specific medication therapy. This “untreated” 
population was younger and had a lower percentage of 
women than the treated populations. Most notably, use of 
NSAIDs and controlled painkillers was common in the 
untreated migraine group and nearly of equal prevalence 
with use among those receiving only acute migraine-specific 
therapy. Untreated migraine patients had higher rates for 
all ten of the comorbid conditions explored compared with 
those receiving only acute migraine therapies but utilized 
less overall psychotropic pharmacotherapy (15% versus 
17%). Together with prior research suggesting that triptans 
are started in only 5% of all migraine patients, these findings 
raise questions about whether there is therapeutic inertia 
against appropriate use of acute migraine medications in 
some patients and what factors might be influencing this 
pattern of care.38
Psychiatric comorbidity
This study found that patients with migraine were often 
diagnosed with comorbid depression, anxiety, bipolar 
spectrum disorders, and more often prescribed medications 
commonly used to treat insomnia, attention-deficit 
disorder, and psychosis. Additionally, nearly one in three 
migraine patients received psychotropic drugs (other than 
anticonvulsants or antidepressants) not routinely used for 
migraine treatment. These psychotropic drugs were used 
twice as frequently among migraine patients as in the control 
group (30% versus 14%, respectively). More than half of 
migraine patients who received any psychotropic drug had 
their psychotropic prescribed by a primary care provider.
Psychiatric comorbidity has been associated not only 
with an increased susceptibility to headaches but also 
with potential refractoriness to migraine drug therapy and 
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chronification of migraine.39 Substance abuse, illicit drug use, 
and nicotine dependence have also been linked to migraine.13 
Despite the recognition of a bidirectional association between 
migraine and psychiatric disorders, this linkage has been 
frequently clinically discussed but seldom systematically 
studied. Future studies are needed to better understand the 
migraine to mental health connection and optimal treatment 
setting and approach for patients with both migraine and 
psychiatric comorbidities.
Study limitations
This claims-based study had limitations that need to be 
understood in interpreting the data. As in all claims-based 
analyses, the data were not collected for research but 
for administrative billing purposes, which might lead to 
misclassification of migraine and comorbidity diagnoses. 
Selected drug prescribing for 12 months after an ICD-9 
migraine diagnosis that appeared in the authors’ claims history 
was assessed; this permitted examination of the subsequent 
12-month-period prevalence of co-medication use. Whether 
the co-medications were prescribed to specifically treat the 
patients’ migraine or other conditions (eg, depression or 
anxiety) is not known. However, in comparing the migraine 
patients with the control group, it is clear that the prevalent 
use of most of the co-medications was higher in the migraine 
patients. The study sample in this study included ICD-9-
diagnosed patients and/or those receiving MSAMs; patients 
with undiagnosed migraine or those who did not seek 
physician care for their headaches were not included. Further, 
the sample was biased toward patients who sought care, who 
most likely had more severe headaches, more comorbidity, 
and more co-medications than individuals who did not seek 
care; however, this study provides valuable information for 
the segment of the US migraine population seeking care for 
their migraine disorder.
Conclusion
This study supports existing perspectives on migraine as 
a complex disorder with significant variability in drug 
treatment patterns and medical and psychiatric comorbidities. 
The active utilization of migraine preventive medications is 
relatively low, particularly for FDA-approved drugs. Nearly 
one-third of patients who used high levels of triptans did not 
receive any preventive therapy. Despite preventive therapy, 
many patients were high triptan users and utilized other 
analgesics, such as NSAIDs and controlled painkillers. 
Comorbidity was common; especially interesting was the 
authors’ observations of associations between migraine and 
various psychiatric conditions and their treatments. The 
majority of migraine patients receive their acute medications 
and other psychotropic medications from primary care 
physicians rather than neurologists or psychiatrists. 
Additional research is needed to better understand patterns 
of resource use by patients with migraine and the potential 
role of other health care professionals, such as pharmacists, 
to help promote evidence-based migraine care and improve 
patient outcomes. Given their visibility to and knowledge 
of prescription histories for patients, pharmacists have the 
opportunity to play a key role in identifying those patients 
with migraine for whom preventive medication may be 
indicated and beneficial, particularly for those patients 
demonstrating a pattern of triptan or other acute analgesic 
overuse.
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Appendix 1 Markers used to identify migraine patients from pharmacy and medical claims
Medical claim with ICD-9 code for migraine or related phenomenon during 2008 346*, 784, 339*
Pharmacy claim for migraine-specific acute medication Any triptan 
Any ergotamine
Notes: ICD-9 code descriptors: 346* (migraine), 784 (headache), 339* (other headache syndromes, eg, complicated headache syndrome); *denotes code extensions   
0.00 through 0.99, inclusive. 
Abbreviation: ICD-9, International Classification of Diseases, Ninth Revision.8
Appendix 2 Classification of drug markers
Acute migraine 
medications
Preventive migraine 
medications
Psychotropic 
drugs
Controlled 
painkillers*
Prescription 
NSAIDs**
Ergotamines 
Triptans 
Almotriptan 
Eletriptan 
Frovatriptan 
Naratriptan 
Rizatriptan 
Sumatriptan 
Zolmitriptan
US FDA approved 
Divalproex 
Propanolol 
Timolol 
Topiramate 
Other potential preventives 
Antidepressants 
Antihypertensives 
Anticonvulsants 
Miscellaneous 
Baclofen 
Cyproheptadine
New generation hypnotics 
Anxiolytics 
Benzodiazepines 
Buspirone 
Antipsychotics 
Atypical antipsychotics 
Typical antipsychotics 
Mood Stabilizer (lithium) 
Stimulants 
Amphetamines 
Atomoxetine 
Modafinil
Opioids 
+/- APAP 
+/- caffeine 
+/- NSAID 
Butalbitals 
+/- ASA/caffeine 
+/- APAP/caffeine 
+/- codeine 
Isometheptene 
Butorphanol NS
Mefenamic acid 
Indomethacin 
Ibuprofen 
Fenoprofen 
Tolmetin 
Naproxen 
Flurbiprofen 
Sulindac 
Meclofenamate 
Piroxicam 
Diclofenac 
Ketoprofen 
Ketorolac 
Etodolac 
Nabumetone 
Oxaprozin
Notes: *Only oral forms of these painkillers were used as drug markers with the exception of butorphanol nasal spray (NS); **only prescribed NSAIDs were used as drug 
markers, over-the-counter NSAIDs not part of the database. 
Abbreviations: ASA, acetylsalicylic acid; APAP, acetaminophen; NSAIDs, nonsteroidal anti-inflammatory drugs; US FDA, US Food and Drug Administration.
Appendix 3 Other comorbid diagnostic conditions identified in the study population
Diagnostic condition clusters ICD-9 codes used
Depression (unipolar) 296.2*, 296.3*, 300.4, and 311
Anxiety disorders 293.84, 300.0*, 300.2*, 300.3, and 309.81
Bipolar spectrum disorders 296.0*, 296.1*, 296.4*, 296.5*, 296.6*, 296.7, 296.80, 296.89, and 301.13
Chronic pain 307.8, 307.80, 338, 338.0, 338.2, 338.29, and 338.4
Arthritis 274*, 714.0, 714.1, 714.2, 714.3, 714.30, 714.31, 714.33, 714.4, 714.89, 714.9, 715*, 716*, 720.0, and 721*
Fibromyalgia 728.87, 728.89, and 729.1
Sinusitis 461* and 473*
Hypertension 401*, 402*, 403*, 404*, 405*, 642*, and 997.91
Diabetes 249*, 250*, 362.0, 366.41, and 648.0*
Epilepsy 345*, 780.39, and 649.4*
Note: *Any numerical code extensions of the root code number. 
Abbreviation: ICD-9, International Classification of Diseases, Ninth Revision.8
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